{"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}],"groups":[{"description":"Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \\[Car-BiRD\\]\n\nCar Phase:\n\ncarfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.\n\nBiRD Phase:\n\nClarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nLenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nDexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nMaintenance Phase:\n\nLenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.","id":"BG000","title":"Car-BiRD Therapy"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"85","value":"60.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}],"title":"Car Phase"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"85","value":"59.6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"58"}],"units":"Participants"}],"title":"BiRD Phase"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"79","value":"59.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"Maintenance Phase"}],"dispersionType":"FULL_RANGE","paramType":"MEAN","populationDescription":"72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects reached the BiRD Phase of the CarBiRD therapy. 54 subjects reached the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"43"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}],"title":"Car Phase"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"58"}],"units":"Participants"}],"title":"BiRD Phase"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"31"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"Maintenance Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects reached the BiRD Phase of the CarBiRD therapy. 54 subjects reached the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"61"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}],"title":"Car Phase"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"48"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"58"}],"units":"Participants"}],"title":"BiRD Phase"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"45"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"Maintenance Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"29"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"72"}],"units":"Participants"}],"title":"Car Phase"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"58"}],"units":"Participants"}],"title":"BiRD Phase"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"Maintenance Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow."}